Related Experiment Videos
Long-term parathyroid- and c-cell function after radioiodine for benign thyroid diseases
Lene S Mortensen1, Kamille Smidt, Anette Jørgensen
1Viborg County Hospital, Department of Internal Medicine, Viborg, Denmark.
Basic & Clinical Pharmacology & Toxicology
|June 10, 2005
Summary
Radioiodine treatment for benign conditions is safe for parathyroid hormone and calcitonin secretion. Long-term studies show normal hormone levels and secretion capacity after radioiodine therapy.
Area of Science:
- Endocrinology
- Nuclear Medicine
Background:
- Radioiodine (radioactive iodine) is commonly used for benign thyroid conditions.
- Potential long-term effects on parathyroid and thyroid C-cells require investigation.
Purpose of the Study:
- To evaluate the long-term effects of radioiodine on parathyroid hormone (PTH) and calcitonin secretion.
- To assess the safety of radioiodine therapy regarding endocrine function.
Main Methods:
- Retrospective study of patients 8-12 years post-radioiodine treatment for benign conditions.
- Measurement of baseline calcium and PTH levels.
- Assessment of PTH and calcitonin secretion capacity using hypocalcemic and hypercalcemic stimulation tests.
Main Results:
- Baseline calcium and PTH levels were within normal ranges 8-12 years after radioiodine.
- No significant differences in stimulated PTH or calcitonin secretion were observed compared to controls.
Conclusions:
- Radioiodine, at doses used for benign thyroid diseases, appears safe for parathyroid and calcitonin secretion.
- Long-term endocrine function related to these hormones is not adversely affected by radioiodine therapy.